The American Society for Radiation Oncology released an updated evidence-based clinical practice guideline published in Practical Radiation Oncology, recommending moderate hypofractionated radiation therapy across all localized prostate cancer risk classifications. The comprehensive clinical update synthesizes multi-year trial data comparing abbreviated radiation schedules against traditional multi-week therapeutic regimens, establishing refined treatment standards for oncologists worldwide.
The revised guidelines conclude that delivering higher individual radiation doses over shorter four- to six-week schedules achieves long-term oncologic control and disease-free survival rates equivalent to conventional eight- to nine-week protocols. Long-term follow-up studies also demonstrated similar urinary and bowel toxicity rates between the approaches. By endorsing shorter treatment courses as the primary standard of care, ASTRO emphasized that patients benefit from greater convenience, reduced travel burdens, and lower overall medical costs without sacrificing clinical efficacy.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.eurekalert.org/news-releases/1149425